Omnicare - Chapter 11 APA Summary
Omnicare obtained approval of the sale of substantially all assets to stalking horse bidder GenieRx Holdings for $250 million in cash plus the assumption of liabilities, following cancellation of the auction and the Debtors' determination (in consultation with the Consultation Parties) that the stalking horse bid was the highest or otherwise best offer for the assets, with sale proceeds to be applied toward repayment of DIP obligations up to the aggregate outstanding amount of the DIP obligations.
Bidding Procedures / Asset Purchase Agreement Summary
Parties Involved
- Seller: Omnicare, LLC, a Delaware limited liability company ("Seller")
- Asset Sellers (also called Liquidating Debtors): Seller and the other Debtors listed on Schedule 1.01(c) to the Amended and Restated Asset Purchase Agreement dated Sept. 30, 2026 (the "Amended APA"). They sell the Purchased Assets and liquidate under the Chapter 11 Plan after Closing.
- Acquired Entities (also called Reorganizing Debtors): the Subsidiaries of Seller listed on Schedule 1.01(b), including the Purchased Entities, but excluding the Asset Sellers. Buyer acquires them by acquiring their equity under the Chapter 11 Plan.
- Purchased Entities:
- NeighborCare Pharmacy Services, LLC
- JHC Acquisition LLC
- Badger Acquisition of Kentucky LLC
- D&R Pharmaceutical Services, LLC
- Evergreen Pharmaceutical of California, LLC
- Best Care LTC Acquisition Company LLC, which the Debtors anticipate will be renamed "Omnicare Payroll, LLC"
- NCS Healthcare of Kentucky, LLC, which does business as Vangard Labs ("Vangard Labs")
- Any additional Debtors designated in the Plan Supplement to become employers of record for Business Employees
- CVS Pharmacy, Inc. ("CVS"): owns all equity of Omnicare, LLC; transfers the Domain Names and CVS FF&E to Buyer; and is a service provider under the Transition Services Agreement.
- Purchaser: GenieRx Holdings LLC, a Delaware limited liability company, or its designees (collectively, the "Buyer"), as the Stalking Horse Bidder and Successful Bidder. Integro Asset Management LLC is an Affiliate of Buyer.
- The Buyer is not an "insider" or "affiliate" of the Debtors as those terms are defined in the Bankruptcy Code, and is not a "successor" to, a mere continuation of, or an alter ego of the Debtors or their estates. There is no common identity of incorporators, directors, or controlling stockholders between the Debtors and the Buyer.
Amendment Motion and Order
- On Oct. 5, 2026, the Debtors filed an emergency motion [Docket No. 1327] seeking authority to enter into and perform under:
- the Amended APA, which amends, restates and supersedes the March 31, 2026 APA (the "Original APA") in its entirety; and
- a Transition Services Agreement (the "TSA") among CVS, Seller and Buyer, which revises the form TSA attached to the Original APA.
- Following a hearing on Oct. 27, 2026, the Court entered an order [Docket No. 1382] (the "Amendment Order") granting the motion and the Debtors' related supplement [Docket No. 1374]. It authorizes the Debtors to enter into and perform under:
- the Amended APA;
- the amended TSA; and
- an amendment to the Amended APA (the "Second APA Amendment," titled "First Amendment to Amended and Restated Asset Purchase Agreement").
- The Sale Order permits modifications to the Original APA without further order if they do not have a material adverse effect on the Debtors' estates. The Debtors assert the amendments have no such effect, but sought approval out of an abundance of caution and because the amended agreements are key to implementing the Plan.
- The Amended APA does the following:
- shifts the Sale to a partial equity transaction that the Sale Order contemplated as a possibility;
- conforms the transaction to the Second Amended Joint Chapter 11 Plan of Reorganization and Liquidation [Docket No. 1267], which the Court confirmed on Sept. 16, 2026 [Docket No. 1280];
- adjusts the closing date;
- makes certain purchase price and assumed liability adjustments; and
- resolves various business separation and transition issues.
- The Second APA Amendment further:
- reduces the Closing Cash Consideration by the Accrued Compensation for certain employees participating in a long-term incentive plan, which Buyer distributes to those employees (see Employee Matters);
- increases the Closing Cash Consideration by the Additional Vangard Inventory Amount (see Additional Vangard Inventory);
- adds the Chapter 11 Plan as a basis for the purchase and sale under Section 2.01; and
- extends the latest Extended End Date from Nov. 23, 2026 to Nov. 30, 2026.
- Base cash consideration remains $250,000,000, subject to certain customary closing adjustments, plus the assumption of assumed liabilities.
- Supporting declaration: Andrew Turnbull, Managing Director in the Financial Restructuring Group at Houlihan Lokey Capital, Inc., the Debtors' investment banker.
- Status of the case:
- The Debtors resolved the $1 billion judgment against Omnicare in the FCA Action and the claims between the Debtors and CVS Health through agreements the Court approved on Aug. 12, 2026 [Docket No. 1113].
- The Debtors anticipate that Holders of General Unsecured Claims will receive a 100% recovery under the Plan.
- Closing and Plan effectiveness remain subject to obtaining regulatory approvals, replacing key business functions currently provided by the CVS Entities, and other transition matters.
- The Amendment Order provides:
- The Amended APA is the definitive asset purchase agreement governing the Sale.
- It is entitled to all rights, protections, findings and approvals granted under the Sale Order for the Original APA, except as expressly modified by the Amendment Order and the Confirmation Order.
- The Sale Order and Confirmation Order otherwise remain in full force and effect.
- The Amendment Order is effective immediately, notwithstanding Bankruptcy Rules 4001(a)(3) or 6004(h).
Transaction Structure
- Seller sells to Buyer all Purchased Equity Interests (all issued and outstanding equity of the Purchased Entities) under the Amended APA and the Chapter 11 Plan. As a result, Buyer acquires the Acquired Entities.
- The Asset Sellers sell and assign the Purchased Assets and Assumed Liabilities to Buyer and Buyer Designees under the Amended APA, the Chapter 11 Plan, the Confirmation Order and the Sale Order.
- Except for Owned Real Property of the Acquired Entities, which is conveyed to Buyer by quit claim deed, the assets of the Acquired Entities remain with those entities and are not transferred separately to Buyer.
- Carved-Out Assets and Carved-Out Liabilities are to be transferred out of the Acquired Entities to Seller or a non-Acquired Entity Affiliate of Seller. Failure to complete a transfer before Closing does not change an item's characterization.
- Effective as of the Closing Date, each Reorganizing Debtor becomes a reorganized debtor entitled to the discharge under section 1141(d)(1) of the Bankruptcy Code.
- The Chapter 11 Plan and Confirmation Order provide:
- a permanent injunction under section 524(a) against pursuing discharged, released or exculpated Claims, Interests and Causes of Action against the Reorganized Debtors, Buyer and Buyer Designees; and
- that those parties incur no successor, transferee, de facto merger or similar derivative liability for pre-Closing Claims and Causes of Action, provided that Buyer and the Reorganized Debtors remain responsible for the Business Liabilities.
- Equity Locations are pharmacies and other locations owned or operated by an Acquired Entity. Asset Locations are those owned or operated by an Asset Seller and conveyed as Purchased Assets. All Acquired Pharmacies are Equity Locations except those designated as Asset Locations on Schedule 1.01(d).
Assets Being Sold
- The Business consists of prescription drug distribution, medication management and pharmaceutical consulting services to the following facilities:
- assisted living facilities;
- skilled nursing facilities;
- facilities within the Mental Health Group Home segment; and
- Intermediate Care Facilities for Individuals with Intellectual and Developmental Disabilities.
- The Business includes:
- dispensing, packaging, labeling and delivering prescription and over-the-counter medications;
- clinical pharmacy, medication therapy management and medication review services;
- pharmacy consulting on regulatory compliance, formulary management and drug utilization review;
- infusion and specialty infusion therapy;
- dispensing of medical supplies and durable medical equipment; and
- acting as a pharmaceutical repackager.
- Purchased Assets include all of the Asset Sellers' right, title and interest in all assets related to the Business (other than Excluded Assets), plus the Owned Real Property of the Acquired Entities. Among other items:
- All accounts receivable, trade receivables, notes and other similar claims for money due to any Asset Seller;
- All inventory owned by the Asset Sellers used or held for use in connection with the Business, including all prescription merchandise located at the Acquired Pharmacies;
- Assigned Contracts with vendors, suppliers and customers of the Business;
- Leasehold interests of the Asset Sellers in Leased Real Property and the related Assigned Leases;
- Owned Real Property of the Asset Sellers and the Acquired Entities, together with all facilities, structures, improvements, fixtures, easements and rights of way;
- Furniture, fixtures, equipment, vehicles, and other tangible personal property used in the Business;
- Assigned Intellectual Property Assets (other than the Domain Names, which are being sold by CVS);
- All prescription files, records and data utilized, maintained, or generated by the Asset Sellers in the course of operating the Acquired Pharmacies ("Asset Seller Rx Data");
- Copies of all Books and Records exclusively related to the Business;
- Acquired Avoidance Actions and other claims and causes of action arising from the other Business Assets or Business Liabilities;
- Rights to all telephone and facsimile numbers for the Acquired Pharmacies;
- Prepaid expenses, credits, advance payments, rights of recovery, set-off, recoupment, deposits, charges and fees;
- Rights of indemnity, warranty rights, guaranties and other rights of recovery against other Persons;
- The Purchased Equity Interests;
- Insurance benefits relating to material damage or destruction of tangible personal property or leasehold improvements included in the Purchased Assets, for events first occurring after the Effective Date and before Closing;
- Bank accounts relating exclusively to the Business (other than the Excluded Bank Accounts); and
- All goodwill with respect to the other Purchased Assets.
- Separately, Seller will cause CVS to sell, assign and transfer to Buyer all of CVS's right, title and interest in the Domain Names and the CVS FF&E.
- Excluded Assets (Asset Sellers) and Carved-Out Assets (Acquired Entities) include, among other items:
- all Cash and Cash Equivalents;
- affiliate receivables;
- Enterprise Contracts;
- any "CVS" marks;
- pre-Closing Actions other than Acquired Avoidance Actions;
- consolidated Tax Returns;
- equity interests in the Asset Sellers and the Heartland Entities (non-Debtor Subsidiaries of Seller);
- Benefit Plans; and
- sale-related documents and privileged materials.
- Enterprise Contracts are not assigned to Buyer. These are Contracts entered into by non-Debtor Affiliates, intercompany cash management or back-office contracts with CVS, oral contracts, and contracts relating in part to other CVS businesses. The "Caremark Agreement" is an Assigned Contract and not an Enterprise Contract.
- Up to two Business Days before Closing, Buyer may designate any Business Contract as an Excluded Asset or Carved-Out Asset without any reduction in the Purchase Price.
- The sale is free and clear of all liens, claims, interests, and encumbrances, except for the Assumed Liabilities and Permitted Encumbrances.
Purchase Price
- The aggregate Purchase Price for the Purchased Assets consists of:
- Closing Cash Consideration; plus
- The assumption of the Assumed Liabilities.
- Closing Cash Consideration equals $250,000,000, adjusted as follows:
- minus the PTO Excess Adjustment Amount, if the Assumed PTO Amount exceeds the $6,000,000 Assumed PTO Cap;
- plus the PTO Rollover Deficit Adjustment Amount, if the Assumed PTO Amount is below the Assumed PTO Cap;
- minus a positive Proration Adjustment Amount, or plus the absolute value of a negative Proration Adjustment Amount;
- minus the $2,500,000 Recoupment Adjustment Amount, in exchange for Buyer becoming responsible for certain healthcare recoupment charges;
- plus Lease Termination Costs;
- minus the Accrued Compensation, which Buyer distributes to Impacted LTIP Participants (see Employee Matters); and
- plus the Additional Vangard Inventory Amount, currently estimated at approximately $1,000,000 (see Additional Vangard Inventory).
- At least two Business Days before Closing, Seller delivers a Closing Statement. It sets out the PTO amounts, Proration Adjustment Amount, Recoupment Adjustment Amount, Lease Termination Costs, Additional Vangard Inventory Amount and the resulting adjustment to the Closing Cash Consideration, with supporting information.
- At Closing, Buyer pays Seller the Closing Cash Consideration minus the Deposit by wire transfer and directs the Escrow Holder to disburse the Deposit to Seller. If Closing occurs on a non-Business Day, payment is due the next Business Day.
- Separately, Buyer pays Seller $11,900,000 for payroll obligations, on or before the date Seller funds its portion of the Straddle Period Payroll (see Employee Matters). The Turnbull declaration describes this payment as akin to a working capital peg.
Assumed Liabilities
- Buyer assumes only the following Liabilities of the Asset Sellers, without duplicating the Acquired Entity Retained Liabilities:
- Cure Claims for Assigned Contracts and Assigned Leases, and accounts payable and trade payables for goods received or services rendered to the Business after the Petition Date and before Closing. These are capped at $30,000,000 in the aggregate, inclusive of the corresponding Cure Claims and trade payables retained by the Acquired Entities. The cap increased from $25,000,000 because Specified Court Approval was obtained within 20 days after the date of the Original APA.
- All Liabilities under the Assigned Contracts (other than the CVS Clean Harbors Liabilities and Business Cure Claims) and Assigned Leases (other than Business Cure Claims), but only to the extent they:
- are required to be performed after the Closing Date;
- were incurred in the ordinary course; and
- do not arise from any pre-Closing breach or default.
- The Assumed Employee Liabilities:
- the post-Closing portion of the Straddle Period Payroll;
- the Assumed PTO; and
- other Liabilities Buyer agrees to assume under the employee matters provisions.
- Recoupments as to which no liquidated proof of claim was filed in the Chapter 11 Cases (other than Recoupments discharged by the Bankruptcy Court), and Prorations; and
- All other Liabilities arising out of or relating to the ownership, use or operation of the Purchased Assets after Closing.
- The Acquired Entities retain parallel Liabilities (the "Acquired Entity Retained Liabilities"), which Buyer must cause the Acquired Entities to pay after Closing.
- Carved-Out Liabilities are all other Liabilities of the Acquired Entities. They include:
- Business Cure Claims and Business Trade Payables above the caps;
- employee Liabilities other than the Assumed Employee Liabilities;
- Indebtedness not paid in full at Closing; and
- pre-Closing Claims, Interests and Causes of Action discharged, released or exculpated under the Chapter 11 Plan and Confirmation Order.
- All Liabilities of the Asset Sellers not expressly assumed are Excluded Liabilities. This includes Liabilities arising from any failure to comply with bulk sales or tax clearance laws.
Cure Claims
- Buyer, the Buyer Designees or the applicable Acquired Entity shall satisfy all Liabilities required to be paid under section 365 of the Bankruptcy Code to assume and assign the Business Contracts and Business Leases. This applies to contracts assigned to Buyer or the Buyer Designees, or assumed by an Acquired Entity, on or after the Closing Date under the Sale Order or the Chapter 11 Plan.
- Payment is due on the Closing Date or the date of assignment or assumption (or, if later, when otherwise due).
- Business Cure Claims are capped at $1,000,000 in the aggregate; any excess is a Carved-Out Liability or Excluded Liability.
- The combined Business Cure Claims and Business Trade Payables are capped at $30,000,000. If they exceed that amount, Buyer must deliver a written statement at least five Business Days before Closing identifying the specific claims and payables it will assume or retain, totaling $30,000,000.
- Under the Sale Order, counterparties that did not timely object to the Assumption Notices are deemed to have consented at the proposed Cure Claim amount and are barred from asserting additional Cure Claims or defaults.
Good Faith Deposit
- Buyer delivered a Deposit of $20,020,000 into a segregated escrow account. This consists of:
- the original $19,670,000; plus
- an additional $350,000 that became payable, and was paid, because Specified Court Approval was obtained within 20 days after the date of the Original APA.
- If Closing does not occur on or before Oct. 31, 2026, Buyer must increase the Deposit by an additional $3,000,000 on Nov. 2, 2026.
- At Closing, the Deposit will be released to Seller and credited toward payment of the Purchase Price.
- If the Amended APA is terminated by Seller under Section 9.01(c) or 9.01(d) (for Buyer's breach or failure to close), Seller may retain the Deposit, together with any accrued interest, as liquidated damages.
- If the Amended APA is terminated for any other reason under Section 9.01, the Deposit will be returned to Buyer as soon as reasonably practicable.
Bid Protections
- Specified Court Approval was obtained within 20 days after the date of the Original APA. Seller is therefore obligated to pay Buyer, in consideration of Buyer's due diligence, good faith negotiation, entry into the APA and its work in establishing a bid standard:
- A Break-up Fee of $8,580,000 (increased from $8,430,000); and
- An Expense Reimbursement of up to $1,500,000 (increased from $0). It covers reasonable out-of-pocket expenses, including legal and accounting expenses, Auction participation, and prosecution of Bankruptcy Court approval of Buyer as a good faith buyer.
- "Specified Court Approval" means entry of an Order amending the Bidding Procedures Order so that the Bid Protections provide for:
- a break-up fee equal to 3% of the transaction value; and
- reimbursement of the buyer's reasonable and documented out-of-pocket costs and expenses as the Stalking Horse Bidder, up to an additional $1,500,000.
- The Break-Up Fee and Expense Reimbursement constitute administrative expenses allowable under section 503(b)(1) of the Bankruptcy Code.
- The Break-up Fee and Expense Reimbursement are earned upon Seller accepting a bid for an Alternative Transaction. They are payable from the proceeds upon closing of that Alternative Transaction, without further Bankruptcy Court approval or order.
Auction Details
- Following extensive marketing and in consultation with the Consultation Parties, the Debtors cancelled the Auction and determined that the Stalking Horse Bid was the Successful Bid and the Stalking Horse Bidder was the Successful Bidder, as reflected in the Notice of Cancellation of Auction and of Successful Bidder [Docket No. 799].
- The marketing and sale process afforded a full, fair, and reasonable opportunity for any Potential Bidder to make a higher or otherwise better offer. It was conducted in a diligent, non-collusive, fair, reasonable, and good-faith manner, and obtained the highest or otherwise best value for the Purchased Assets, with no other transaction or combination of transactions available or presented that would have yielded a higher or better result.
Highest and Best Offer
- The APA constitutes the highest or otherwise best offer for the Purchased Assets. The Debtors, in consultation with the Consultation Parties, determined that the transactions contemplated by the APA maximize value for the benefit of the Debtors' estates, creditors, stakeholders, and parties in interest.
- Entry into the APA constitutes a valid and reasonable exercise of the Debtors' business judgment consistent with their fiduciary duties and in compliance with the Bidding Procedures and the Bidding Procedures Order.
- No other person, entity, or group has offered to purchase the Purchased Assets for greater economic value to the Debtors, and the APA provides fair and reasonable terms for the purchase.
Good Faith Finding
- The APA was negotiated, proposed, and entered into by the Debtors and the Buyer without collusion or fraud, in good faith, and from arm's-length bargaining positions. The Buyer has not acted in a collusive manner with any Person, has not entered into any agreement with any other potential bidders, and has not colluded with any potential or actual bidders.
- Among other things:
- the Debtors were free to deal with any other interested party;
- the Debtors and the Buyer complied with the Bidding Procedures Order and the Bidding Procedures;
- the Buyer agreed to subject its bid to the Bidding Procedures;
- the Debtors and the Buyer actively participated in the marketing and sale process in good faith;
- all payments and arrangements by the Buyer in connection with the Sale have been disclosed; and
- the Buyer was designated the Successful Bidder in accordance with the Bidding Procedures and the Bidding Procedures Order.
- The Buyer is a good-faith purchaser within the meaning of section 363(m) of the Bankruptcy Code and is entitled to the full rights, benefits, privileges, and protections thereunder. The Sale may not be avoided under section 363(n) of the Bankruptcy Code.
- The protections afforded by section 363(m) are integral to the Sale, and the Buyer would not consummate the Sale without them. Reversal or modification on appeal will not alter, affect, limit, or otherwise impair the validity of the Sale (including the assumption, assignment, and/or transfer of the Assigned Contracts and Assigned Leases), unless duly stayed pending such appeal.
- The Debtors assert that the Amended Agreements are likewise the product of good-faith, arm's-length negotiations among the Debtors, Buyer and CVS Pharmacy.
No Fraudulent Transfer
- The Transaction Documents are valid and binding contracts between the Debtors and the Buyer, and were not entered into for the purpose of hindering, delaying, or defrauding creditors.
- The consideration provided by the Buyer:
- is fair and reasonable;
- is the highest or otherwise best offer for the Purchased Assets;
- will provide a greater recovery for the Debtors' creditors more expeditiously than any other practical available alternative; and
- constitutes reasonably equivalent value and fair consideration under the Bankruptcy Code and applicable state laws, including the Uniform Fraudulent Conveyance Act, Uniform Voidable Transactions Act, and Uniform Fraudulent Transfer Act.
Not a Sub Rosa Plan
- Neither the APA nor the Sale constitutes a sub rosa chapter 11 plan or an element of such plan, impermissibly restructures the rights of the Debtors' creditors, or impermissibly dictates the terms of the Debtors' subsequent chapter 11 plan.
Sale Free and Clear & Successor Liability
- Pursuant to sections 105(a), 363(b), 363(f), 365(b), and 365(f) of the Bankruptcy Code, the Debtors shall transfer the Purchased Assets, including the Assigned Contracts and Assigned Leases, to the Buyer free and clear of all Liens, Claims and other Interests, with the exception of the Permitted Encumbrances and the Assumed Liabilities. This includes Interests arising under or related to any Healthcare Laws, Permit, or Provider Numbers, as well as participation in any Government Health Program.
- The conditions of section 363(f) of the Bankruptcy Code have been satisfied in full with respect to each Interest in the Purchased Assets:
- Holders of Interests who did not timely object, or who withdrew objections, are deemed to have consented under section 363(f)(2).
- All other Interests fall within one or more of the subsections of section 363(f).
- All holders of Interests are adequately protected.
- Any valid and perfected Interests in the Purchased Assets shall attach to the cash proceeds of the Sale with the same validity, force, and effect, and in the same order of priority, as against the Purchased Assets.
- The Sale does not amount to a consolidation, succession, merger, or de facto merger of Buyer and the Debtors. Except as expressly set forth in the APA, the transfer of the Purchased Assets and assumption of the Assumed Liabilities will not subject the Buyer to any liability whatsoever, including any successor liability, under any theory of successor, transferee, derivative, vicarious or assignee liability. This covers antitrust, environmental, revenue, pension, ERISA, tax, labor (including any WARN Act), employment or benefits, de facto merger, business continuation, substantial continuity, alter ego, veil piercing, escheat, continuity of enterprise, mere continuation, product line, or products liability laws.
- Notwithstanding the foregoing, nothing herein precludes the National Labor Relations Board or any court from finding that any purchaser of the Debtors' assets is subject to a successor collective bargaining obligation under the National Labor Relations Act in accordance with NLRB v. Burns International Security Services, 406 U.S. 272 (1972) and applicable law.
- Following Closing, no holder of any Interests (other than those expressly assumed by the Buyer or Permitted Encumbrances) may interfere with the Buyer's use and enjoyment of the Purchased Assets.
Assumption and Assignment
- The Debtors filed and served the Assumption and Assignment Notice. It contained:
- the list of executory contracts and unexpired leases that may potentially be assumed and assigned in connection with the Sale;
- information necessary to provide notice of the proposed assumption and assignment;
- Cure Costs, where applicable; and
- the procedures and deadlines for objecting to the assumption and assignment and related Cure Costs.
- Pursuant to sections 105(a), 363, and 365 of the Bankruptcy Code, and subject to and conditioned upon Closing, the Debtors are authorized and directed to:
- assume and assign to the Buyer, effective upon the Closing Date, the Assigned Contracts and Assigned Leases free and clear of all Interests (other than Permitted Encumbrances and Assumed Liabilities and as otherwise required by the APA); and
- execute and deliver such documents as Buyer deems necessary to assign and transfer the Assigned Contracts, Assigned Leases, and Assigned Permits.
- Pursuant to section 365(f) of the Bankruptcy Code, each Assigned Contract or Assigned Lease shall be assigned and transferred to the Buyer notwithstanding any provision prohibiting, restricting, or conditioning its assignment or transfer.
- The Debtors' or Buyer's obligations to pay the Cure Costs upon the Closing Date, and Buyer's obligations to perform thereafter, constitute adequate assurance of future performance within the meaning of sections 365(b)(1) and 365(f)(2) of the Bankruptcy Code. Payment of the Cure Costs is deemed to fully satisfy the Debtors' obligations under section 365(b).
- All Counterparties to the Assigned Contracts and Assigned Leases that failed to timely file and serve an objection are forever barred from asserting any such objection.
- To the extent any Assigned Contract or Assigned Lease is not an executory contract or unexpired lease within the meaning of section 365, it shall be transferred to the Buyer in accordance with the terms applicable to the Purchased Assets.
- The foregoing assumption and assignment remains subject to the Court's determination of the Debtors' Motion for Entry of an Order Authorizing the Assumption of Certain Unexpired Leases of Nonresidential Real Property and Granting Related Relief [Docket No. 782] (the "Assumption Motion"). The Nonresidential Real Property Leases identified on Schedule 1 to the Assumption Motion shall only be deemed Assigned Leases assumed and assigned to the Buyer to the extent the Court grants the relief requested in the Assumption Motion.
Sale in Best Interests
- Approval of the Transaction Documents and the Sale is appropriate under the circumstances of the Chapter 11 Cases and in the best interests of the Debtors, their estates, their creditors and other parties in interest.
- The Debtors have demonstrated good, sufficient, and sound business purposes and justifications, and compelling circumstances, for the Sale other than in the ordinary course of business under section 363(b) and outside of a plan of reorganization or liquidation. Immediate consummation of the Sale is necessary to maximize the value of the Debtors' estates, subject to the regulatory approvals and other conditions set forth in the APA.
- Time is of the essence in consummating the Sale, and the Buyer would not consummate the Sale without all of the relief provided for in the Sale Order.
DIP Financing
- The DIP facility is provided under the Senior Secured, Super-Priority Debtor-in-Possession Loan and Security Agreement dated Nov. 3, 2025, with JMB Capital Partners Lending, LLC as lender (the "DIP Lender").
- Under the Final DIP Order [Docket No. 257] and the DIP Credit Agreement, until Payment in Full of the Obligations, the Purchased Assets and their proceeds constitute DIP Collateral and Cash Collateral.
- Upon receipt of any Net Cash Proceeds from the sale of the Purchased Assets, the Borrowers shall pay those proceeds to the DIP Lender, up to the aggregate outstanding amount of the Obligations, in accordance with the Final DIP Order and the DIP Credit Agreement.
- If Closing does not occur on or before Oct. 31, 2026, Buyer reimburses Seller for 50% of any fees payable to the DIP Lender to extend the DIP facility to Nov. 30, 2026, up to $250,000, payable Nov. 2, 2026.
Employee Matters
- Transfer of employees:
- Immediately before Closing, CVS will cause all Business Employees to transfer to the Employment Entity. The Employment Entity is Best Care LTC Acquisition Company LLC, to be renamed "Omnicare Payroll, LLC", plus any additional Debtors designated in the Plan Supplement.
- Excluded from that transfer are Disabled Employees and Direct Hire Business Employees, meaning those working for the Acquired Pharmacies listed on Schedule 6.06(a).
- At Closing, Buyer or its designee becomes the sole equityholder of the Employment Entity.
- Buyer offers employment to Direct Hire Business Employees and retains Business Employees who continue with the Employment Entity.
- Terms of employment:
- Terms must be communicated not more than four weeks and at least three weeks before the Closing Date.
- Positions must be the same or substantially comparable.
- Base salary or wages and annual cash bonus opportunity must be no less than before Closing.
- Employee benefits must be substantially comparable in the aggregate, excluding defined benefit pension plans, retiree medical arrangements, equity compensation and Severance Benefits.
- Disabled Employees remain with Seller. If a Disabled Employee is released to return to work within six months after Closing, Buyer must make an employment offer within 10 Business Days of notice.
- For H-1B Employees who accept offers, Buyer must file portability or transfer petitions three Business Days before Closing, at Buyer's cost.
- Buyer assumes COBRA obligations for qualifying events on or after the Closing Date; Seller retains pre-Closing COBRA Liabilities.
- Straddle Period Payroll is a "hard cutover":
- Seller funds the pre-Closing portion through its payroll processor.
- Buyer, its Affiliates or the Employment Entity fund the post-Closing portion.
- Because Buyer no longer assumes pre-Closing accrued payroll (as it had agreed under the Original APA), Buyer pays Seller $11,900,000 on or before the date Seller funds its portion.
- Accrued PTO:
- Buyer assumes and honors Accrued PTO not paid out (the "Assumed PTO"), crediting each Transferred Employee's leave account no later than the first Business Day after Closing.
- Eligible Employees (those outside Mandatory Payout Jurisdictions) are asked to consent to rolling over their Accrued PTO.
- Employees who request cash-out make a Voluntary Cash-Out Election; employees who do not respond receive a Default PTO Payout.
- Seller pays the Voluntary Cash-Out, Default and Mandatory PTO Payout Amounts.
- PTO price adjustments against the $6,000,000 Assumed PTO Cap:
- If the Assumed PTO Amount exceeds the cap, Closing Cash Consideration is reduced by the excess.
- If it is below the cap, Closing Cash Consideration is increased by the Mandatory PTO Payout Amount (up to the shortfall), plus the lesser of the remaining shortfall or 33% of the Voluntary Cash-Out and Default PTO Payout Amounts.
- In no event may the Assumed PTO Amount plus this increase exceed the cap.
- Long-term incentive plan (LTIP), added by the Second APA Amendment:
- Certain Business Employees participate in LTIPs sponsored by an Affiliate of Seller, with stock awards vesting on March 31, 2027 for employees still employed by Seller or its Affiliates on that date.
- As a result of the Sale, non-retirement eligible participants (the "Impacted LTIP Participants") will not be eligible to receive those awards.
- By Nov. 30, 2026, the Debtors will have accrued and paid $1,416,299.20 to an Affiliate of Seller to satisfy these compensation obligations. The amount will be adjusted to its value as of the Closing Date (the "Accrued Compensation").
- Closing Cash Consideration is reduced by the Accrued Compensation.
- At or before Closing, Seller delivers a schedule listing the Impacted LTIP Participants, the awards that would have vested for each, and the Accrued Compensation allocable to each.
- Buyer pays the Accrued Compensation, net of withholding taxes and the employer portion of payroll taxes, pro rata based on the awards that would have vested, to Transferred Employees who:
- remain continuously employed by Buyer or its Affiliates from Closing through March 31, 2027; or
- are no longer employed on that date due to death, disability or termination without cause.
- Payments are due no later than the second regularly scheduled payroll date after March 31, 2027. Within five Business Days of that payment deadline, Buyer delivers Seller and CVS a schedule of the payments made.
- Buyer may not retain any portion of the Accrued Compensation. Amounts not paid to eligible employees, plus the related unwithheld tax portion, must be returned to Seller within five Business Days after that payroll date.
Additional Vangard Inventory
- At Buyer's request, Seller has caused or will cause one or more Acquired Entities or Asset Sellers to order generic pharmaceutical inventory for the Vangard Labs repackaging facility. The quantities represent approximately one additional month of supply above the levels customarily maintained at the facility (the "Additional Vangard Inventory").
- Closing Cash Consideration is increased by the invoiced purchase price of the Additional Vangard Inventory that has been or will be paid on or before the Closing Date by Seller, any Asset Seller, any Acquired Entity or their Affiliates, including CVS (the "Additional Vangard Inventory Amount"). The Debtors currently estimate this amount at approximately $1,000,000.
- Seller sets out the Additional Vangard Inventory Amount in the Closing Statement and must cause it to be paid on or before the Closing Date.
- Buyer's request constitutes its written approval for purposes of Seller's interim operating covenants. The purchase and any resulting increase in inventory or trade payables is not a breach of Seller's representations, warranties or covenants, and is not taken into account in determining whether closing conditions are satisfied.
- Neither Seller nor any Asset Seller is obligated to take possession of the Additional Vangard Inventory. Buyer must cause Vangard Labs or an Affiliate to accept any deliveries made after Closing, and the Additional Vangard Inventory Amount is not reduced for inventory paid for before Closing but delivered afterward.
Closing Extension
- If Closing does not occur on or before Oct. 31, 2026, Buyer must:
- reimburse 50% of the DIP Extension Fees to Nov. 30, 2026, up to $250,000, payable Nov. 2, 2026;
- reimburse Seller's reasonable out-of-pocket expenses (excluding DIP Extension Fees) up to $250,000 per week from Nov. 1, 2026 through the earlier of Closing or Nov. 30, 2026. Amounts are pro-rated for partial weeks and paid in advance on the first Business Day of each week, starting Nov. 2, 2026; and
- increase the Deposit by $3,000,000 on Nov. 2, 2026.
- Any delay or failure to obtain a title commitment, title policy or survey, or to complete other diligence on the Owned Real Property, shall not delay or preclude Closing and is not a failure of a closing condition.
Facility Closures
- If Buyer and Seller agree in writing (email being sufficient) to close any pharmacy location before Closing, or to begin the closing process before Closing, the costs are allocated as follows:
- Seller pays the related Severance Benefits ratably over the severance period, and Buyer reimburses Seller for those payable after Closing.
- Seller pays landlord termination fees for Business Leases terminated with Buyer's consent ("Lease Termination Costs"), which Buyer repays at Closing as an increase to Closing Cash Consideration.
- Seller shall use commercially reasonable efforts to help minimize Lease Termination Costs, including through Hilco Valuation Services, LLC and, if applicable, the Bankruptcy Court.
- Business Leases for closing pharmacies may only be terminated with Buyer's prior written consent, and Buyer may elect to assume rather than terminate them.
Leased Vehicles
- On or before Closing, Buyer will enter into a contract with Wheels LT under which it assumes the Liabilities of CVS and its Affiliates under the CVS enterprise vehicle lease (the "Wheels Contract") relating solely to vehicles used by the Asset Sellers and Acquired Entities. This is conditioned on terms substantially similar to the Wheels Contract.
- Seller pays any separation or assignment costs for removing CVS's other vehicles from the Wheels Contract; these are Excluded Liabilities.
Prorations
- Prorations cover:
- real estate taxes, ad valorem taxes and special assessments on Owned Real Property;
- ad valorem personal property taxes; and
- rent, common area maintenance charges, taxes and utilities under the Business Leases.
- The Proration Adjustment Amount equals Seller's good faith estimate of unpaid pre-Closing Prorations minus post-Closing Prorations already paid by the Debtors. Each is calculated on a per-day basis.
- If actual taxes are unknown at Closing, the prior year's amounts are used.
- Buyer may deliver a corrected Prorations Statement within 60 days after Closing. Seller has 30 days to object, and unresolved disputes after 45 days go to an Accounting Referee, whose fees are split equally.
Regulatory Matters and Conditions to Closing
- The parties agree that no HSR Act filing is required for the Amended APA, and no closing condition is based on any HSR waiting period.
- Buyer must take any and all actions necessary to resolve impediments under antitrust, privacy or trade regulation laws, including divestitures and hold-separate arrangements, provided such actions are conditioned on Closing.
- Buyer must use reasonable best efforts to transfer or obtain new Healthcare Permits on or before the End Date.
- Conditions to all parties' obligations:
- receipt of the governmental approvals listed on Schedule 7.01(a);
- no Order making the transactions illegal; and
- entry of the Sale Order and the Confirmation Order, neither stayed, vacated, reversed or materially modified.
Patient Records
- Asset Locations: custody of and responsibility for Asset Seller Patient Records transfers to Buyer as of the Closing Date.
- Equity Locations: the applicable Acquired Entity remains the Continuing Provider, Covered Entity and Records Custodian of the Acquired Entity Patient Records. No change in custodianship, and no patient authorization or consent, is required.
- Seller bears the cost of extracting electronic Transferred Records; Buyer bears the cost of ingesting them.
- Neither Buyer nor any Acquired Entity assumes HIPAA or Patient Record Liabilities arising before completion of the Migration.
Post-Closing Arrangements
- Transition Services: CVS and Seller will provide post-Closing Transition Services to Buyer, excluding the Excluded Services. The parties must finalize the services, including the duration and cost of each, on or before Oct. 21, 2026. CVS is not obligated to use extraordinary efforts, engage third parties or incur material out-of-pocket expenditures except as set forth in the TSA.
- Potential services listed in Exhibit G to the Amended APA:
- IT end-user device support, telecommunications, network, data center and hosting, IT security, production environment support and corporate application support;
- facility security;
- accounts payable pass-through;
- travel and expense (maximum three months);
- business unit accounting;
- sales and use tax; and
- a Divestiture Management Office.
- TSA services and fees:
- Services are provided with commercially reasonable efforts, substantially consistent with pre-Closing practice and in full compliance with applicable Law.
- The Exhibit A services schedule is blank in the approved form.
- Fees are the lesser of the Exhibit A charge and actual cost.
- Costs are reconciled quarterly, within 30 days after quarter-end, and any overpayment is refunded to Buyer.
- TSA invoicing:
- Invoices are monthly and due within 30 days.
- Late amounts bear interest at up to 7% per annum.
- Invoices may be disputed only for documented billing errors, within 10 Business Days of receipt, through an escalation process.
- TSA term and termination:
- Buyer must prepare a Migration Plan within 60 days after Closing.
- Services may be extended up to two three-month extensions with CVS's consent.
- Buyer may terminate services for convenience on 30 days' notice, but Dependent Services must be terminated together.
- Either side may terminate for uncured material breach after 30 days (15 days for payment defaults).
- TSA liability:
- Liability is capped at fees paid for the Service giving rise to the claim.
- CVS's and Omnicare's liability is several, not joint.
- Indemnification is mutual, covering breach and gross negligence or willful misconduct.
- TSA access and records:
- Buyer must give Omnicare (as Plan Administrator) and CVS access to books, records and knowledgeable personnel until the sixth anniversary of Closing, for wind-down, regulatory, tax and claims administration purposes.
- Access is extended for any Claims or Insured Claims matters still pending at that date until they are finally resolved.
- Other TSA provisions:
- access and security, confidentiality, and HIPAA business associate terms;
- a limited license from Buyer to the Service Providers to use the Buyer Marks, including "Omnicare"; and
- work-for-hire treatment of Deliverables.
- Payor Agreements: If assignment of a Payor Agreement is not effective by Closing, Buyer may use it until the earlier of 12 months after the Sale Order Date or effective assignment. Buyer indemnifies the Asset Sellers for its use.
- Healthcare Permits not yet transferred may be used under a Power of Attorney for up to 90 days after Closing, extendable by 30 days.
- Following Closing, each Asset Seller shall change its corporate name to a name not including "Omnicare" as soon as reasonably practicable, and in any event within 30 Business Days after the Closing Date, unless applicable Law or the Bankruptcy Court requires otherwise.
Texas Taxing Authorities
- Any ad valorem taxes owed to the Texas Taxing Authorities for tax year 2026 that are secured by property being acquired by the Buyer (the "2026 Ad Valorem Tax Claims") shall be paid and allocated between the Debtors and Buyer as set forth in the APA.
- The Texas Taxing Authorities shall retain their respective liens arising from the 2026 Ad Valorem Tax Claims against the Purchased Assets, as applicable, until paid in full, including any applicable penalties or interest.
- The tax liens of the Texas Taxing Authorities for tax year 2025 and prior years, if any, shall attach to the sale proceeds of any property that is the subject of such liens. All rights to object to the priority, validity, amount, and extent of any tax claims of the Texas Taxing Authorities are fully preserved.
Reservation of Rights of the United States
- Nothing in the Sale Order shall:
- release, nullify, preclude, or enjoin the enforcement of any police or regulatory power or liability of an owner, lessor, lessee, or operator of property after entry of the Sale Order;
- affect the setoff or recoupment rights of the United States;
- confer exclusive jurisdiction to the Bankruptcy Court except to the extent set forth in 28 U.S.C. § 1334;
- authorize the assumption, assignment, sale or other transfer of any Federal Interests without compliance by the Debtors and Buyer with all terms thereof and applicable non-bankruptcy law;
- be interpreted to set cure amounts or require the United States to novate, approve, or otherwise consent to the transfer of any Federal Interests;
- waive, alter, or limit the United States' property rights; or
- expand the scope of 11 U.S.C. § 525.
- In the event of any inconsistency between the Transaction Documents and the Sale Order, as to the United States, the provisions of the Sale Order and federal law shall govern.
Preserved Objections
- Notwithstanding anything to the contrary, the specific objections listed on Exhibit B to the Sale Order (the "Preserved Objections") are preserved in all respects. They will be either consensually resolved or continued to a date to be set by the Court and resolved by separate order, with all rights of affected parties to appeal such separate orders preserved.
- The Preserved Objections shall be resolved prior to any Closing of the Sale, unless otherwise separately ordered by the Court after notice and an opportunity for a hearing.
- All valid and timely objections to assumption and assignment of any applicable Assigned Contract or Assigned Lease, including to proposed Cure Costs, are preserved.
- The Preserved Objections are those filed by:
- Chicago Industrial Portfolio Owner LLC
- Plymouth International Spellmire OH LLC
Termination
- The Amended APA may be terminated at any time prior to Closing:
- By mutual written consent of Seller and Buyer;
- By Buyer, upon written notice to Seller, for an uncured material breach by Seller (provided Buyer is not then in material breach);
- By Seller, upon written notice to Buyer, for an uncured material breach by Buyer (provided Seller is not then in material breach);
- By Seller, if all closing conditions have been satisfied or waived, Seller has indicated in writing it is ready, willing and able to close, and Buyer fails to close by the earlier of three Business Days after the date the Closing should have occurred and the End Date;
- By Seller or Buyer, upon written notice, if Closing has not occurred by the End Date. This right is unavailable to a Party whose material breach or failure to perform caused the failure to close. Subject to compliance with the Closing Extension covenants, Buyer has one option, exercisable on or before the End Date, to extend the End Date to a date no later than Nov. 30, 2026 (extended from Nov. 23, 2026 by the Second APA Amendment);
- By Seller or Buyer, upon written notice, if the Bankruptcy Court approves an Alternative Transaction, meaning any agreement under which the Acquired Equity Interests and substantially all of the Purchased Assets will be acquired by, or transferred to, a third party. Buyer's right to terminate on this basis is subject to its obligation to serve as a Back-Up Bidder, and if Buyer is later designated a Successful Bidder after becoming a Back-Up Bidder, it shall comply with all applicable provisions of the Amended APA; or
- By Seller or Buyer, upon written notice, if the Bankruptcy Court enters a final non-appealable Order that otherwise precludes the consummation of the transactions, subject to any limitations in the Bidding Procedures Order or other Bankruptcy Court Order. A Party may not terminate on this basis if its material breach is the primary cause of such Order.
Approval and Authorization
- The APA and other Transaction Documents, including any amendments, supplements, and modifications thereto, are approved in their entirety.
- Pursuant to sections 105(a), 363, and 365 of the Bankruptcy Code and Bankruptcy Rules 2002, 6004, and 6006, the Debtors are authorized and empowered to take any and all actions necessary or appropriate to:
- consummate the Sale;
- close the Sale as contemplated in the APA and the Sale Order; and
- execute, deliver, perform under, consummate and implement the APA and other Transaction Documents, including the assumption and assignment of the Assigned Contracts and Assigned Leases.
- The Debtors are further authorized to pay, without further order of the Court, any amounts that become payable by the Debtors pursuant to the APA and other Transaction Documents.
- The APA, the other Transaction Documents and the Sale Order are binding upon:
- the Debtors and their estates;
- all creditors, holders of equity interests and holders of Claims;
- all holders of Liens or other Interests against any portion of the Purchased Assets;
- all counterparties to any executory contract or unexpired lease (including all Counterparties);
- the Buyer; and
- all successors and assigns of each of the foregoing, including any chapter 7 or chapter 11 trustee subsequently appointed.
Notice
- Proper, timely, and adequate notice of the Motion, the Sale Hearing, the Auction (and cancellation thereof), the Sale, the Assumption and Assignment Procedures, the Assumption and Assignment Notice, the Cure Costs, the Successful Bidder Notice, and all related transactions and deadlines was provided.
- Notice complied with sections 102(1), 363, and 365 of the Bankruptcy Code, Bankruptcy Rules 2002, 9007, 9008, and 9014, Local Rule 9007-1, section E of the Complex Case Procedures, and the Bidding Procedures Order.
- Notice is evidenced by the certificates of service filed at Docket Numbers 299, 427, 670, 733, 796, and 806, and was posted on the website of the Debtors' claims and noticing agent, Stretto, Inc.
- Such notice was good, sufficient, and appropriate under the circumstances, and no other or further notice is necessary or required.
Objections Overruled
- All other objections to, reservations of rights regarding, or other responses to the Motion or the relief requested therein, the APA and other Transaction Documents, the Sale, the entry of the Sale Order, or the relief granted therein have been resolved, withdrawn, or overruled.
- Parties that did not timely object, or who withdrew their objections, are deemed to have consented to the relief granted, including pursuant to section 363(f)(2) of the Bankruptcy Code.
Other Provisions
- Bulk Sales: No "bulk sales," "bulk transfer," or any similar law (including those relating to taxes) of any state or other jurisdiction shall apply in any way to the transactions authorized, including the APA and Sale.
- California Successor Liability Agreement: At Closing, Seller and Buyer each execute a Successor Liability with Joint and Several Liability Agreement in substantially the form provided by the State of California Health and Human Services Agency.
- Seller Counsel: The Debtors' law firms, including Jenner & Block LLP and Quarles & Brady LLP, may represent the Seller Group after Closing notwithstanding their prior representation of the Acquired Entities. Pre-Closing privileged communications relating to the transaction are controlled by Seller.
- Automatic Stay: The automatic stay under section 362 of the Bankruptcy Code is lifted to the extent necessary, without further order of the Court, to allow the Buyer and the Debtors to deliver any notice provided for in the APA and to take any and all actions permitted under the APA and other Transaction Documents.
- Waiver of Stay: For cause shown, under Bankruptcy Rules 6004(h), 6006(d), 7062, and 9014, the Sale Order is not stayed after entry and is effective and enforceable immediately. The stays provided in Bankruptcy Rules 6004(h) and 6006(d) are expressly waived.
- Retention of Jurisdiction: The Bankruptcy Court retains exclusive jurisdiction to interpret, implement, and enforce the Sale Order, the APA and other Transaction Documents, and any amendments, waivers and consents, and to adjudicate all disputes relating to the Sale. This includes jurisdiction to:
- compel delivery of the Purchased Assets to the Buyer;
- interpret, implement, and enforce the provisions of the Sale Order, including the injunctions and limitations of liability;
- decide any disputes concerning the Sale Order and the APA, including disputes regarding the transfer of assets free and clear of all Interests (other than Permitted Encumbrances and Assumed Liabilities) and the resolution of the Preserved Objections; and
- enter any orders under sections 105, 363, and 365 of the Bankruptcy Code with respect to the Purchased Assets and the Assigned Contracts and Assigned Leases.
Key Dates
- Petition Date: Sept. 22, 2025
- Bidding Procedures Order Entered: Dec. 3, 2025 [Docket No. 398]
- Original APA Date: March 31, 2026
- Sale Order Entered: May 13, 2026 [Docket No. 835]
- FCA and CVS Settlement Agreements Approved: Aug. 12, 2026 [Docket No. 1113]
- Plan Confirmed: Sept. 16, 2026 [Docket No. 1280]
- Amended APA Effective Date: Sept. 30, 2026
- Amendment Motion Filed: Oct. 5, 2026 [Docket No. 1327]
- Transition Services Finalization Deadline: Oct. 21, 2026
- Amendment Motion Hearing: Oct. 27, 2026
- Amendment Order Entered: Oct. 28, 2026 [Docket No. 1382]
- End Date: Oct. 31, 2026 (extended from Sept. 30, 2026)
- Closing Extension Payments and Deposit Increase Due: Nov. 2, 2026 (if Closing has not occurred by Oct. 31, 2026)
- Extended End Date: no later than Nov. 30, 2026, at Buyer's option (extended from Nov. 23, 2026)
- DIP Extension Date: Nov. 30, 2026
- LTIP Vesting Date / Accrued Compensation Payout Reference Date: March 31, 2027